NASDAQ:IMRN Immuron (IMRN) Stock Price, News & Analysis $1.22 +0.09 (+7.96%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$1.23 +0.01 (+0.82%) As of 05:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Immuron Stock (NASDAQ:IMRN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Immuron alerts:Sign Up Key Stats Today's Range$1.11▼$1.2350-Day Range$0.89▼$1.4552-Week Range$0.68▼$2.39Volume35,619 shsAverage Volume52,435 shsMarket Capitalization$9.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia. Read More Immuron Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreIMRN MarketRank™: Immuron scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingImmuron has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageImmuron has only been the subject of 1 research reports in the past 90 days.Read more about Immuron's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioImmuron has a P/B Ratio of 1.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Immuron's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.97% of the float of Immuron has been sold short.Short Interest Ratio / Days to CoverImmuron has a short interest ratio ("days to cover") of 1.96, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immuron has recently decreased by 48.41%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmuron does not currently pay a dividend.Dividend GrowthImmuron does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.30 News SentimentImmuron has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Immuron this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for IMRN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Immuron insiders have not sold or bought any company stock.Percentage Held by Insiders7.01% of the stock of Immuron is held by insiders.Percentage Held by Institutions0.12% of the stock of Immuron is held by institutions.Read more about Immuron's insider trading history. Receive IMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immuron and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMRN Stock News HeadlinesImmuron CEO to Present TechKnow Invest Roadshow in MelbourneJuly 21 at 6:50 AM | tipranks.comImmuron CEO, Steven Lydeamore presentation at Kalkine Media WebinarJuly 20 at 8:42 AM | markets.businessinsider.comYour First Trade Playbook is expiringMost beginners stay stuck on the sidelines for years because no one shows them the simple steps between being interested in options and actually placing a trade. Your First Trade Playbook closes that gap in one evening - and right now it is still free. Bill Poulos plans to charge for it soon, so download your copy before the temporary link expires.July 22 at 1:00 AM | Profits Run (Ad)Immuron Showcases Oral Antibody Platform in July 20 Investor PresentationJuly 20 at 8:30 AM | tipranks.comImmuron Reports FY26 Global Sales Up 6% on Strong Travelan Growth in Australia and the U.S.July 16, 2026 | quiverquant.comQImmuron FY26 Sales - Four Consecutive Quarters of Growth over Prior YearJuly 16, 2026 | globenewswire.comImmuron Engages Pullan Consulting to Advance IMM-529 Partnering StrategyJuly 6, 2026 | quiverquant.comQImmuron Advances IMM-529 (Clostridioides difficile infection) Partnering StrategyJuly 6, 2026 | globenewswire.comSee More Headlines IMRN Stock Analysis - Frequently Asked Questions How have IMRN shares performed this year? Immuron's stock was trading at $0.7680 at the start of the year. Since then, IMRN shares have increased by 58.9% and is now trading at $1.22. When did Immuron IPO? Immuron (IMRN) raised $6 million in an IPO on Friday, June 9th 2017. The company issued 600,000 shares at $9.99 per share. Joseph Gunnar and Rodman & Renshaw (a unit of H.C. Wainwright & Co.) served as the underwriters for the IPO and WallachBeth Capital was co-manager. How do I buy shares of Immuron? Shares of IMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immuron own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immuron investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), AbbVie (ABBV), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP) and Dynavax Technologies (DVAX). Company Calendar Today7/21/2026Next Earnings (Estimated)8/28/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 IMRN's financial health is in the Green zone, according to TradeSmith. IMRN has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryN/A Current SymbolNASDAQ:IMRN CIK1660046 Webwww.immuron.com.au Phone(138) 892-4854Fax6103 98227735EmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio8.04 Quick Ratio6.83 Sales & Book Value Annual Sales$4.72 million Price / Sales2.09 Cash FlowN/A Price / Cash FlowN/A Book Value$0.78 per share Price / Book1.56Miscellaneous Outstanding Shares8,070,000Free Float7,505,000Market Cap$9.85 million OptionableNot Optionable Beta1.16 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:IMRN) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredWhat most options traders never learn before their first tradeMost options losses don't come from picking the wrong trade - they come from traders who never understood how ...Base Camp Trading | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | Sponsored30-Year market veteran reveals America’s #1 StockMarket veteran Jim Woods has flagged triple-digit gains multiple times in under two months - 151% on Netflix, ...Eagle Publishing | SponsoredForget SpaceX… this is the REAL #1 IPO of 2026While SpaceX and OpenAI dominate IPO headlines, one private company is reportedly seeing the fastest revenue g...The Oxford Club | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuron Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuron With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
